MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-33-0025864
Iqgen-X Pharma Private Limited - pharma in Navi Mumbai, Maharashtra, India. FY 2026 financials & compliance.
Revenue · FY 2023
₹8.51 Cr
▼ 14% YoY
Net loss · FY 2023
₹25.88 Lakh
Net margin -3%
EBITDA · FY 2023
₹1.16 Cr
EBITDA margin 13.7%
Authorised capital
₹2 Cr
Registered with MCA
Paid-up capital
₹1.13 Cr
Issued & subscribed
Open charges
₹2.28 Cr
Secured borrowings
Company age
10 yrs
Est. 2016
Employees · EPFO
34
Provident fund records
About Iqgen-X Pharma Private Limited
Data last updated:
Iqgen-X Pharma Private Limited is a private limited company based in Navi Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 13 October 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U74999MH2016PTC286716. Its GSTIN is 27AAECI2779P1ZT (Maharashtra).
The company has an authorised share capital of ₹2 Cr and a paid-up capital of ₹1.13 Cr. It is led by directors including Madhu Hariharan and Mandar Madhukar Kodgule.
Its last annual general meeting (AGM) was held on 30 September 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at A – 165 Ttc Industrial Area Khairane., Navi Mumbai, Maharashtra, India – 400705.
As per the financials filed for FY 2023, the company reported a revenue of ₹8.51 Cr, a decline of 14% compared to the previous year. For the same year it recorded a net loss of ₹25.88 Lakh (net margin -3%) and EBITDA of ₹1.16 Cr (EBITDA margin 13.7%). Revenue has grown at a compounded annual rate (CAGR) of 4% over three years and 23% over five years.
The company has about 34 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: IQGEN-X Pharma. As per MCA filings, the company has open charges of ₹2.28 Cr on record. The company has 8 deals on record (4 funding rounds, 3 secondary share transfers, 1 acquisition), with disclosed funding of ₹11.73 Cr; the latest was in August 2026.
Iqgen-X Pharma Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-33-0025864). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website iqgenx.com.
Company details
CIN U74999MH2016PTC286716
Registration Number 286716
Incorporation Date 13 October 2016
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2023
Date of Balance Sheet 31 March 2023
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-MH-33-0025864
Recognitions & Rankings of Iqgen-X Pharma
Contact details
Iqgen-X Pharma Private Limited's registered office is in Navi Mumbai, Maharashtra. Its website is iqgenx.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressA – 165 Ttc Industrial Area Khairane., Navi Mumbai, Maharashtra, India – 400705
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Iqgen-X Pharma Private Limited, buy the company report.
Comprehensive company report
Iqgen-X Pharma Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Iqgen-X Pharma operates one associated brand: IQGEN-X Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Solid and liquid pharmaceutical formulations are manufactured and developed. | iqgenx.com |
Business activity
The main business activity of Iqgen-X Pharma is professional, scientific and technical. In detail, this covers scientific research and development.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Iqgen-X Pharma Private Limited, buy the company report.
Financials of Iqgen-X Pharma Private Limited
FY 2023 filings availableIqgen-X Pharma Private Limited reported revenue of ₹8.51 Cr (down 14% YoY) for FY 2023.
Revenue · FY 2023
₹8.51 Cr ▼ 14%
Net loss · FY 2023
₹25.88 Lakh margin -3%
EBITDA · FY 2023
₹1.16 Cr margin 13.7%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 14%
3 years · compounded
▲ 4%
5 years · compounded
▲ 23%
EBITDA CAGR growth
1 year
▲ 698%
3 years · compounded
▼ 14%
5 years · compounded
▲ 59%
Revenue fell 14% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 23%. EBITDA rose 698% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹8.51 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.16 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹25.88 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 13.7% | ||||
| Net Profit Margin | -3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Iqgen-X Pharma Private Limited, buy the company report.
Board of directors of Iqgen-X Pharma Private Limited
Iqgen-X Pharma has 5 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Madhu Hariharan | Director | 01 Apr 2017 | 9 Years 6 Months | Current |
| Mandar Madhukar Kodgule | Director | 01 Apr 2017 | 9 Years 6 Months | Current |
| Yogita Mandar Kodgule | Director | 01 Apr 2017 | 9 Years 6 Months | Current |
| Yatendra Kumar | Director | 01 Apr 2017 | 9 Years 6 Months | Current |
| Parizad Adil Elchidana | Additional Director | 30 Sep 2021 | 5 Years 0 Months | Current |
Auditor
Iqgen-X Pharma Private Limited is audited by DIPTI TAPARIA & COMPANY for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DIPTI TAPARIA & COMPANY | FY 2023 | 152764W |
Shareholding
The shareholding of Iqgen-X Pharma Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Iqgen-X Pharma Private Limited, buy the company report.
Charges & borrowings
Open charges
₹2.28 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 28 Jul 2020 | 100355277 | Canara Bank | ₹28 Lakh | Open | |
| 25 Sep 2017 | 100135679 | Canara Bank | ₹2 Cr | Open |
To see the full charge records of Iqgen-X Pharma Private Limited, buy the company report.
Total charge records: 2 View all charges
Deals & funding
Iqgen-X Pharma Private Limited has 8 deals on record (4 funding rounds, 3 secondary share transfers, 1 acquisition), with disclosed funding of ₹11.73 Cr; the latest was in August 2026.
Total deals
8
Funding rounds
4
Secondary share transfers
3
Acquisition
1
Disclosed funding
₹11.73 Cr
Deals on record (5 of 8)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Aug 2026 | Acquisition | ₹9.12 Cr | Buyer: Alivus Life Sciences Limited |
| Mar 2021 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: an individual |
| Oct 2020 | Funding round | ₹10 Cr | Investors: Acg Associated Capsules Private Limited |
| Mar 2018 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 4 individuals |
| Mar 2018 | Funding round | ₹69.6 Lakh | Investors: an individual |
To see the full deal history of Iqgen-X Pharma Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Iqgen-X Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Iqgen-X Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Iqgen-X Pharma Private Limited has a workforce of 34 employees on its EPFO records as of Apr 03, 2024, across 1 active EPFO establishment.
Employee count
34
Active EPFO establishments
1
Employee growth
-5.56%
GST
Iqgen-X Pharma has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAECI2779P1ZT | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Iqgen-X Pharma Private Limited, buy the company report.
Recent activity
Iqgen-X Pharma Private Limited has 13 board changes on record since 2016: 9 appointments and 4 cessations. The latest: Karan Jasjit Singh ceased to be Additional Director on 27 Jan 2026.
Ceased
Karan Jasjit Singh ceased to be Additional Director.
AGM
Iqgen-X Pharma Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.
Filing
Iqgen-X Pharma Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Mumbai Ii.
Appointed
Parizad Adil Elchidana was appointed as Additional Director.
Ceased
Prabhakaran Balakrishnan Nair ceased to be Additional Director.
Appointed
Karan Jasjit Singh was appointed as Additional Director.
Appointed
Prabhakaran Balakrishnan Nair was appointed as Additional Director.
Charges
A charge with Canara Bank of Rs. 2.00 Cr registered on 25 Sep 2017 with Charge ID 100135679 was modified on 29 Aug 2020.
Charges
A charge with Canara Bank amounted to Rs. 0.28 Cr with Charge ID 100355277 was registered on 28 Jul 2020.
Ceased
Mousumi Satyanarayana Vemula ceased to be Director.
Charges
A charge with Canara Bank amounted to Rs. 2.00 Cr with Charge ID 100135679 was registered on 25 Sep 2017.
Appointed
Madhu Hariharan was appointed as Director.
7 earlier events are in the company report.
Frequently asked questions
Iqgen-X Pharma is an active private limited company based in Navi Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 13 October 2016 (10+ years old) and is registered under CIN U74999MH2016PTC286716.
Iqgen-X Pharma has 5 current directors:
- Madhu Hariharan - Director
- Mandar Madhukar Kodgule - Director
- Yogita Mandar Kodgule - Director
- Yatendra Kumar - Director
- Parizad Adil Elchidana - Additional Director
The latest financial statements of Iqgen-X Pharma on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 30 September 2023. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Iqgen-X Pharma is 27AAECI2779P1ZT, registered in Maharashtra.
The CIN (Corporate Identification Number) of Iqgen-X Pharma is U74999MH2016PTC286716. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Iqgen-X Pharma was incorporated on 13 October 2016, making it 10+ years old. It is registered with the Registrar of Companies, Mumbai.
Iqgen-X Pharma has 8 deals on record (4 funding rounds, 3 secondary share transfers, 1 acquisition), with disclosed funding of ₹11.73 Cr; the latest was in August 2026.
Karan Jasjit Singh ceased to be Additional Director on 27 Jan 2026. Parizad Adil Elchidana was appointed as Additional Director on 30 Sep 2021. Prabhakaran Balakrishnan Nair ceased to be Additional Director on 30 Sep 2021. Iqgen-X Pharma has 13 board changes on record in total.
Yes, Iqgen-X Pharma is registered as a small enterprise under Udyam registration (number: UDYAM-MH-33-0025864).
Iqgen-X Pharma can be reached through the website iqgenx.com. Its registered office is in Navi Mumbai, Maharashtra, India.